1. Home
  2. SATL vs GERN Comparison

SATL vs GERN Comparison

Compare SATL & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Satellogic Inc.

SATL

Satellogic Inc.

HOLD

Current Price

$10.44

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.26

Market Cap

821.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SATL
GERN
Founded
2010
1990
Country
United States
United States
Employees
154
258
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
821.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SATL
GERN
Price
$10.44
$1.26
Analyst Decision
Strong Buy
Hold
Analyst Count
3
3
Target Price
$5.50
$2.17
AVG Volume (30 Days)
7.4M
14.2M
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$88.89
$26.91
Revenue Next Year
$56.98
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.26
$1.04
52 Week High
$10.19
$2.01

Technical Indicators

Market Signals
Indicator
SATL
GERN
Relative Strength Index (RSI) 70.43 32.94
Support Level $3.18 $1.24
Resistance Level N/A $1.29
Average True Range (ATR) 0.96 0.09
MACD 0.20 -0.02
Stochastic Oscillator 96.80 10.42

Price Performance

Historical Comparison
SATL
GERN

About SATL Satellogic Inc.

Satellogic Inc is a vertically integrated Earth observation company that designs, manufactures, and operates satellite systems, delivering decision-grade insights at scale to government and commercial customers. Through an end-to-end production and operations model, it provides governments with flexible options across their journey toward sovereign Earth observation. From access to high-frequency imagery and managed space systems to full satellite ownership, to supporting autonomous data availability and long-term technological independence. It has monitoring and alert-driven workflows that help defense and intelligence agencies, civil governments, and commercial operators transition from reactive tasking to proactive decision-making, providing mission-critical data when needed.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: